AUTL Autolus Therapeutics Ltd - ADR

$AUTL New to this ticker. can ppl kindly do a summary of upcoming catalysts and outlook?

$AUTL we will get another pump after earnings or late Dec and Jan 2027. If you wanna sell, sell then. Dont let these people shake you out !

$AUTL The recent pullback was simply a reversion to the mean. AUTL bounced right off the mean and is now heading higher again. As I mentioned in previous posts, the Standard Deviation line has reversed a years-long downtrend and is now moving higher. That matters. Stocks naturally tend to revert toward their mean, so as the mean continues to rise, it creates a higher baseline for the stock. We already know Itan tends to sandbag expectations. If the next earnings report delivers another beat, I believe $3+ going into year-end is very much in play—especially with no meaningful tax-loss selling pressure and the potential for a new 52-week high.

$AUTL 🔥 $AUTL's Management Isn't Looking to License: They're Going to Dominate the Lupus Market Independently While the competition outsources to labs and suffers delays, Autolus's scientific team has vertically integrated from discovery to distribution. Management has proven its ability to move drugs from the UCL lab to FDA approval. Buying $AUTL means buying the best science in Europe! 👑🌍

$AUTL so what has changed with the company since the stock was at $2.50? NOTHING. But it still sucks to see this price.

$AUTL one eighth of the day's trading was in the last thirty minutes. Sellers tried to keep the close below 1.60 but 100K worth of bids came in at the last minute and moved the price back up. A lot of noise before the earnings. Rebalancing should tail off, options are done for now, so maybe we can get back to normal trading sessions instead of these nightly tug of wars.. Q3 earnings will be out soon and we will see where we all stand with AUTL.

$AUTL Itin sandbagging rev guidance more than IOVA. Plus lupus data. Patiently waiting for $9.

$AUTL ⏳ Next stop: Lupus follow-up data release at year-end With over 80 active treatment centers and ongoing expansion in Europe, the market has yet to fully price in the upcoming data on durable response and clear immunity in the high-dose cohort. A clear opportunity ahead of the Q4 clinical update! 🌋📊

$AUTL Caribou halts its allogeneic CAR T programs. Not a direct competitor but they had a CD19-targeting program. One more allogeneic program to fold and demonstrate how difficult to make it in this field.

$AUTL market makers have their racket going. They increase the bid as it gets to 1.80 and increase the ask as it gets to 1.95. Playing both ends, works well on a low float biotech until news/catalyst arrives. They don't care, they make money off other people's money on the spread. Probably even more so with AI, they don't even have to watch it. You see a lot of volume early in the mornings as they set it up and late in the evening when they close it out. Don't like it but its a fact nowadays and will increase as AI Bots/agents take charge of the trading. I'll just stay long and not let them shake the coconuts out of my tree.

$AUTL 🔬 Why Obe-cel Will Outperform the Competition in Autoimmunity (0% ICANS) While other CAR-T therapies send patients to the ICU due to neurotoxicity or severe CRS, Obe-cel registers 0% ICANS and 0% severe CRS thanks to its rapid dissociation engineering. Outpatient administration = Maximum adoption by rheumatologists. Deep remission efficacy without destructive side effects! 🧬🚀

$AUTL Small purchase made. In the grand scheme of things not much added to my portfolio (~1150 shares), but the price was too good to pass up. I may whine from frustration but we will recover! Knocked down avg. another penny! Now $2.71 average 🙌

$AUTL Pull up this post at the end of the year and kick yourself for not taking advantage of this pull back.

$AUTL Really misjudged this one, and I worked there for over a year! Product works great and is loved by clinicians, company not so loved. 🤞That the November catalysts can get me close to my average🤞

$AUTL "The next data update from the Phase 1 CARLYSLE trial with patients in SLE has been submitted for presentation at the American College of Rheumatology (ACR) annual meeting in the fourth quarter of 2026." The meeting dates are November 6-11.

$AUTL hedge fund games. Three weeks before earnings they’ll flip and the stock will fly. Never fails.

$AUTL The activity on this board tells you the interest level this stock had with buyers. If it wasn't for posting good information, thank you 🙏, and me whining there be no activity on the board 😂

$AUTL bought more. The market is wicked..before next ER on November 11th they will pump up to 2$ and above

$AUTL got some buy orders ready. Only worry about the things you can control and the market is not one of them.

$AUTL I asked Hal, my AI Assistant to compare AUTL versus TGTX in progressive MS. This is impotant as TGTX is about 6mths ahead of AUTL and expected to report Ph1 results on 10/23. This is what Hal had to say: Both companies are pursuing CD19-directed CAR-T treatments for progressive MS, but AUTL is using the patient's own cells, while TGTX uses donor-derived cells. TGTX could have an advantage in manufacturing scalability, but AUTL has an important advantage: obe-cel is already FDA-approved for a different indication, meaning there is substantial existing clinical experience with the product. That doesn't establish its efficacy in MS, but it does provide an established manufacturing process and a larger safety database. And here's an interesting consideration: if both companies demonstrate efficacy in progressive MS, we could eventually have a direct commercial comparison between autologous and allogeneic CAR-T approaches in the same disease.